Genome Profiling, LLC (GenPro), an epigenetic biomarker discovery company to clinical research institutions, biopharma and diagnostics companies, announced that Adam Marsh, Ph. D, Chief Science Officer and Co-Founder, will present novel data demonstrating the potential power of epigenetic biomarkers to deliver new clinical value for Companion Diagnostics Applications during The Biomarker Conference, at the Fourpoints by Sheraton Conference Center in San Diego on February 18 – 19, 2016 at 10:30 am in the “Novel Technologies and Approaches” session. Dr. Marsh’s presentation, entitled “Breakthrough Technology for Non-Bisulfite Epigenetic Profiling of DNA Methylation Enables Epigenetic Diagnostic Biomarker Discovery” and will present recent application results of GenPro’s diagnostic platform to identify epigenetic biomarkers (EpiMarkersTM) in patients with acute myeloid leukemia that evidence high confidence in separating between responders and non-responders to a hypomethylating drug therapy in pre-treatment bone marrow biopsies. Overall, DNA methylation is commonly assessed via bisulfite conversion methods and direct next generation sequencing (NGS).
However, resulting nucleotide mutagenesis due to bisulfite oxidation impairs applications of this sequence data for genomic variant call analyses thereby requiring two NGS runs, a sub-optimal and costly consideration. GenPro has developed a novel computational platform for high-resolution, quantitative DNA methylation profiles based on a simple, non-destructive preparation of genomic DNA for next-generation sequencing (Illumina HiSeq X10). GenPro’s technology provides the growing field of clinical epigenetics with sensitive metrics providing unparalleled statistical power in discriminating subtle changes in methylation biomarkers. This power translates into a rapid and cost-effective bioinformatic pipeline for discovery and optimization of epigenetic markers in a range of health applications and across many diseases About Dr. Adam Marsh, Ph. D, CSO & Co-Founder of GenPro: Dr. Marsh, one of the earliest pioneers of computational epigenetics, is the visionary, inventor and leader of GenPro’s core IP and computational capabilities. He and GenPro’s Chief Business Officer, Dr. Didier Landais, will be available throughout the duration of the meeting to discuss GenPro’s Epigenetic Biomarker Discovery Platform and their vision for applying it to “Accelerate the Promise of Precision Health”.
About Genome Profiling LLC:
Genome Profiling (GenPro) specializes in the rapid discovery of novel high-resolution epigenetic biomarkers (EpiMarkers(TM)) from next generation sequencing (NGS) data. Through strategic collaboration agreements with bio-pharma, diagnostic and clinical research institutions, GenPro accelerates the discovery and development of disease and application-specific EpiMarkersTM into clinically and commercially valuable assets – new and better companion diagnostics, precise patient stratification for clinical trials, diagnostics for early disease detection, new drug opportunities, and individualized therapies. GenPro’s value is delivered through its proprietary DNA methylation quantification measurement capabilities which are disruptive to current approaches in that they are much more complete, sensitive, accurate, faster, cost-effective and selective, AND through its EpiMarker Discovery Analytics that transform genome-wide DNA methylation measurements into novel EpiMarkersTM. GenPro also enables BOTH gene variant analysis and epigenetic methylation profiling from ONE NGS run, breaking down the huge cost and time barrier of two separate NGS runs for this highly complementary information.
About The Biomarker Conference: The Cancer Diagnostics Conference will take place February 19 – 20, 2016 at the Fourpoints Sheraton Conference Center in San Diego. With growing pressures of increasing success rates for FDA approved biomarkers, there is a need for a first time right, cost-effective and reliable biomarker discovery and development strategy to secure the essential regulatory approvals. The major challenges faced in securing these approvals include identifying the right biomarkers, understanding disease mechanisms, stratification of patient groups and developing standard protocols and assay platforms. Overcoming these challenges will help in timely discovery, proper validation, robust development of right biomarkers for appropriate application and clinical validation for drug discovery and disease diagnosis.
At ‘The Biomarker Conference’ 150+ biomarker experts will be gathering to discuss emerging pathways and breakthroughs in biomarker discovery and successful validation in consort with the regulatory guidelines and evolving cost-effective technologies that can help increase success rates in novel biomarker discovery and approvals for clinical utility. The main sessions for the conference will be: Biomarker Discovery; Validation and Assay Development; and Clinical Applications of Biomarkers.
More information on the conference can be found [here]
. For additional information contact: Jeb Connor Genome Profiling, LLC email@example.com [www.genprollc.com]
 : http://www.mnmconferences.com/the-biomarker-conference.html